NDAQ:UNCY - Post Discussion
Post by
whytestocks on Jun 25, 2024 7:00pm
Unicycive Therapeutics Achieves Study Objective in Oxylantha
Just In: $UNCY Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial– Successfully Established Favorable Tolerability and Safety of OLC – – New Drug Application (NDA) Submission Anticipated in Q3 2024 – – Webcast and Conference Call Today at 8:30 A.M. ET – LOS ALTOS, Calif., June 25, 2024 (GLOBE NE...
UNCY - Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial
Be the first to comment on this post